Results 41 to 50 of about 20,735 (212)
The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine
Vaccines, 2022 In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford ...Surakameth Mahasirimongkol, Athiwat Khunphon, Oraya Kwangsukstid, Sompong Sapsutthipas, Mingkwan Wichaidit, Archawin Rojanawiwat, Nuanjun Wichuckchinda, Wiroj Puangtubtim, Warangluk Pimpapai, Sakulrat Soonthorncharttrawat, Asawin Wanitchang, Anan Jongkaewwattana, Kanjana Srisutthisamphan, Daraka Phainupong, Naphatcha Thawong, Pundharika Piboonsiri, Waritta Sawaengdee, Thitiporn Somsaard, Kanokphon Ritthitham, Supaporn Chumpol, Nadthanan Pinyosukhee, Rattanawadee Wichajarn, Panadda Dhepakson, Sopon Iamsirithaworn, Supaporn Phumiamorn +24 moredoaj +1 more sourceADEM after ChAdOx1 nCoV-19 vaccine: A case report [PDF]
Multiple Sclerosis Journal, 2021 Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disease of the central nervous system (CNS), clinically defined by an acute polyfocal neurological syndrome usually with monophasic course. ADEM often occurs after infections, but 5%–10% of cases are preceded by vaccinations.Rinaldi V., Bellucci G., Romano A., Bozzao A., Salvetti M. +4 moreopenaire +3 more sourcesHeterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
Vaccines, 2021 Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups.Louise Benning, Maximilian Töllner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kälble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Süsal, Paul Schnitzler, Christian Morath, Claudius Speer +15 moredoaj +1 more sourceComparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants [PDF]
, 2022 Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving three ...Belik, Milja, Häkkinen, Hanni K., Ivaska, Lauri, Jalkanen, Pinja, Julkunen, Ilkka, Kakkola, Laura, Kantele, Anu, Kolehmainen, Pekka, Laine, Larissa, Lempainen, Johanna, Lundberg, Rickard, Miettinen, Simo, Naves, Rauno A., Ortamo, Eeva, Pakkanen, Sari H., Pasternack, Arja, Reinholm, Arttu, Ritvos, Mikael A., Ritvos, Olli, Sironen, Tarja, Skön, Marika, Tahtinen, Paula A., Vapalahti, Olli, Väisänen, Elina, Österlund, Pamela +24 morecore +1 more sourceAugmenting Vaccine Efficacy against Delta Variant with ‘Mycobacterium-w’-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways
Vaccines, 2023 Mycobacterium-w (Mw) was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic.Sarita Rani Jaiswal, Ashraf Saifullah, Jaganath Arunachalam, Rohit Lakhchaura, Dhanir Tailor, Anupama Mehta, Gitali Bhagawati, Hemamalini Aiyer, Subhrajit Biswas, Bakulesh Khamar, Sanjay V. Malhotra, Suparno Chakrabarti +11 moredoaj +1 more sourceCentral nervous system adverse events after ChAdOx1 vaccination
Neurological Sciences, 2022 Post-ChAdOx1 vaccine (AZD1222) adverse events following immunization (AEFI) are uncommon. Recently described neurological events include thrombocytopenia with thrombosis syndrome (TTS) with cerebral venous thrombosis and Guillain-Barré syndrome. There are very few AEFI reports following COVID vaccination from India, because of underreporting or other ...Boby Varkey Maramattom, Radhika Sanjay Lotlikar, Sajith Sukumaran +2 moreopenaire +2 more sourcesDevelopment of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs [PDF]
, 2011 Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in pre-clinical models and clinical trials over the last two decades.Julio Alonso-Padilla, Tibor Papp, Győző L Kaján, Mária Benkő, Menzo Havenga, Angelique Lemckert, Balázs Harrach, Andrew H Baker, Harrach, Benkő, Liu, Reddy, Benevento, Reddy, Rux, Bergelson, Wickham, Wolfrum, Arnberg, Burckhardt, Vectors used in gene therapy clinical trials., Appaiahgari, Pearson, Wilson, Chorny, Van Kampen, George, Ranki, Hendrickx, Ilan, Schaack, Aldhamen, Machitani, Appledorn, Perreau, Minamitani, Khare, Lyons, Carlisle, Seiradake, Xu, Khare, Qiu, Waddington, Kalyuzhniy, Vigant, Alba, Jonsson, Lenman, Doronin, Xu, Eichholz, Ganesan, Alemany, Piccolo, Mocanu, Piccolo, Khare, Xu, Lasaro, Zak, Zhang, Barouch, Bradley, Roberts, Gall, Fausther-Bovendo, Sumida, Miyazawa, Teigler, Smith, Molinier-Frenkel, Heemskerk, Hutnick, Tang, Olive, Leen, Joshi, Osada, Perreau, Seregin, Seregin, Fontanellas, Cerullo, Brunetti-Pierri, Seregin, Farrow, McConnell, Belousova, Seregin, Capasso, Green, Doronin, Kreppel, Matsui, Suzuki-Kouyama, Prill, Krasnykh, Zabner, Havenga, Lecollinet, Coughlan, Granio, Parker, Guse, Smith, Nicol, Bruder, Bruder, Baden, Coughlan, Mück-Häusl, Bi, Abbink, Abbink, Mastrangeli, Abrahamsen, Brough, Stone, Sirena, Stone, Seshidhar Reddy, Hemminki, Creech, Vogels, Kuhn, Di, Havenga, Kahl, Vogels, Lemckert, Teigler, Tameris, Ouédraogo, Keefer, Baden, Gilbert, Baden, Zahn, Johnson, Dakin, Alexander, Alexander, Gurwith, Lemiale, Jarecki-Khan, Saderi, Ko, Bangari, Ayalew, Hammond, Tuboly, Fischer, Hu, Greenall, Brake, Lopez-Gordo, Kremer, Soudais, Soudais, Silva, Puig, Fernandes, Tandon, Bangari, Nguyen, Lenaerts, Ying, van Olphen, Zakhartchouk, Cauthen, Reddy, Reddy, Li, Lenaerts, Sharma, Sharma, Roy, Cohen, Xiang, Quinn, Farina, Roy, Colloca, Barnes, O'Hara, Antrobus, Stanley, Tan, Michou, Ojkic, Sheppard, Corredor, Cherenova, Shashkova, Logunov, Both, Xu, Khatri, Hofmann, Löser, Both, Martiniello-Wilks, Tang, Fraser, Bridgeman, Doszpoly, Cortés-Hinojosa, Wigand, Kajon, Guy, Benkö, Lu, Günes, Wellehan, Phan +215 morecore +4 more sourcesTransient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine
BMJ Case Reports, 2022 Cryoglobulinaemic vasculitis is an immune-complex-mediated, systemic inflammatory syndrome usually involving small-to-medium vessels due to precipitation of cryoglobulins at <37°C. It can involve any organ but most commonly affects the skin. Associated conditions include infections (hepatitis C and HIV), haematological disorders (chronic lymphocytic Sadaf Ahmer, Jack Bourke, Nima Mesbah Ardakani +2 moreopenaire +2 more sourcesEffect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules:exploratory analyses of Com-COV, a randomised control trial [PDF]
, 2022 BACKGROUND: Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV ,, Aley, Parvinder K., Andrews, Nick J., et, al, Finn, Adam, Greenland, Melanie, Lazarus, Rajeka, Liu, Xinxue, Shaw, Robert H., Stuart, Arabella S.V. +9 morecore +6 more sourcesImmunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
PLoS Pathogens, 2023 BackgroundThis study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in primarily vaccinated volunteers with two doses of ChAdOx1-S or BBIBP-CorV.Materials ...Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, Fatemeh Ashrafian, Mona Sadat Larijani, Vicente Verez-Bencomo, Maria Eugenia Toledo-Romani, Carmen Valenzuela Silva, Mostafa Salehi-Vaziri, Sarah Dahmardeh, Delaram Doroud, Mohammad Banifazl, Ehsan Mostafavi, Anahita Bavand, Amitis Ramezani +14 moredoaj +1 more source
